Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Potential Biomarker Determines Risk of Type 2 Diabetes

By LabMedica International staff writers
Posted on 08 Oct 2013
A definitive link has been discovered between certain lifestyle and demographic factors and a potential biomarker to determine the risk of type 2 diabetes.

The biomarker is a protein called sex hormone binding globulin (SHBG) and low levels can be an indication of increased risk for metabolic syndrome and type 2 diabetes years in advance.

Scientists at Brown University (Providence, RI, USA) measured the levels of SHBG in 13,547 women who were a part of the national Women's Health Initiative. More...
Although the team had found that SHBG levels are able to predict the risk of type 2 diabetes, and that several mutations in the genetic coding for the protein are also predictive factors, they say this study shows protein does not necessarily remain unchanged throughout the lifetime of the individual.

Plasma SHBG concentrations were measured using an electrochemiluminescence immunoassay (Roche Diagnostics; Indianapolis, IN, USA), a solid-phase two-site chemiluminescent immunoassay (Siemens Healthcare Diagnostics; Malvern, PA, USA), or an immunoradiometric assay (Esoterix Laboratory Services; Austin, TX, USA).

In the analysis of the results, the scientists found that age, use of estrogen replacement therapy, physical activity, and coffee consumption were significantly higher in women with higher SHBG levels. However, women with a high body mass index (BMI) were linked to low SHBG levels, but the significant associations of SHBG in women did not vary between ethnic groups. The results of the study could also lead to potential new interventions, as BMI, physical activity, estrogen therapy and coffee intake can all be adjusted. The authors noted that by knowing these factors are linked to the biomarker, this suggests changing these elements of lifestyle could, in turn, adjust levels of protein over time, therefore affecting the risk of diabetes.

Simin Liu, MD, ScD, a professor of medicine at Brown, and the senior author of the study said, “This protein seems to capture the cumulative effect between the gene and our environment in reflecting a metabolic state of our body, particularly in the liver, ultimately affecting diabetes risk. By the time you are checking blood glucose it's too late, because you use that as a diagnostic criterion to define diabetes. Our argument is that you can go to the doctor's office and check this protein that can predict your future risk 6 to 10 years down the line." The study was published on September 18, 2013, in the journal Clinical Chemistry.

Related Links:

Brown University
Roche Diagnostics
Siemens Healthcare Diagnostics




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.